D
DNA Chip Research Inc
TSE:2397
DNA Chip Research Inc
TSE:2397
Price:
999 999.9999
JPY
Market Closed
Market Cap:
¥7.4B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
D
|
DNA Chip Research Inc
TSE:2397
|
JP |
|
Shanghai Putailai New Energy Technology Co Ltd
SSE:603659
|
CN |
|
Promotora y Operadora de Infraestructura SAB de CV
BMV:PINFRA
|
MX |
|
M P Evans Group PLC
LSE:MPE
|
UK |
Balance Sheet
Balance Sheet Decomposition
DNA Chip Research Inc
DNA Chip Research Inc
Balance Sheet Decomposition is not available for
DNA Chip Research Inc
DNA Chip Research Inc
Balance Sheet
DNA Chip Research Inc
DNA Chip Research Inc
Currency: JPY
| Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
499
|
355
|
220
|
658
|
302
|
621
|
489
|
275
|
388
|
411
|
|
| Cash Equivalents |
499
|
355
|
220
|
658
|
302
|
621
|
489
|
275
|
388
|
411
|
|
| Total Receivables |
91
|
113
|
129
|
135
|
166
|
150
|
173
|
206
|
190
|
201
|
|
| Accounts Receivables |
71
|
97
|
105
|
113
|
139
|
115
|
124
|
134
|
181
|
200
|
|
| Other Receivables |
20
|
15
|
24
|
22
|
27
|
35
|
49
|
71
|
8
|
1
|
|
| Inventory |
3
|
2
|
6
|
12
|
10
|
3
|
8
|
18
|
68
|
46
|
|
| Other Current Assets |
18
|
8
|
9
|
6
|
53
|
51
|
40
|
26
|
31
|
20
|
|
| Total Current Assets |
611
|
478
|
365
|
810
|
532
|
825
|
710
|
525
|
677
|
678
|
|
| PP&E Net |
47
|
0
|
25
|
15
|
24
|
17
|
2
|
114
|
108
|
133
|
|
| PP&E Gross |
47
|
0
|
25
|
15
|
24
|
17
|
2
|
114
|
108
|
133
|
|
| Accumulated Depreciation |
158
|
169
|
170
|
160
|
177
|
170
|
180
|
187
|
198
|
148
|
|
| Intangible Assets |
2
|
1
|
1
|
36
|
64
|
104
|
142
|
164
|
139
|
122
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
22
|
5
|
4
|
4
|
123
|
74
|
35
|
69
|
59
|
59
|
|
| Total Assets |
682
N/A
|
483
-29%
|
394
-18%
|
865
+119%
|
743
-14%
|
1 021
+37%
|
890
-13%
|
871
-2%
|
982
+13%
|
991
+1%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
20
|
22
|
52
|
48
|
47
|
49
|
47
|
55
|
70
|
64
|
|
| Accrued Liabilities |
20
|
28
|
26
|
30
|
28
|
22
|
31
|
26
|
34
|
70
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
7
|
9
|
14
|
11
|
7
|
10
|
21
|
40
|
105
|
134
|
|
| Total Current Liabilities |
47
|
60
|
93
|
89
|
83
|
82
|
99
|
121
|
209
|
269
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
4
|
5
|
6
|
7
|
7
|
9
|
10
|
39
|
41
|
49
|
|
| Total Liabilities |
51
N/A
|
65
+26%
|
99
+53%
|
96
-4%
|
90
-6%
|
90
+0%
|
110
+21%
|
160
+47%
|
250
+56%
|
317
+27%
|
|
| Equity | |||||||||||
| Common Stock |
1 400
|
1 400
|
1 400
|
416
|
416
|
642
|
642
|
792
|
927
|
927
|
|
| Retained Earnings |
2 082
|
2 294
|
2 417
|
91
|
207
|
382
|
532
|
902
|
1 150
|
1 208
|
|
| Additional Paid In Capital |
1 313
|
1 313
|
1 313
|
444
|
444
|
670
|
670
|
820
|
955
|
955
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
630
N/A
|
418
-34%
|
295
-29%
|
769
+161%
|
653
-15%
|
931
+42%
|
781
-16%
|
711
-9%
|
732
+3%
|
674
-8%
|
|
| Total Liabilities & Equity |
682
N/A
|
483
-29%
|
394
-18%
|
865
+119%
|
743
-14%
|
1 021
+37%
|
890
-13%
|
871
-2%
|
982
+13%
|
991
+1%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
4
|
4
|
4
|
5
|
5
|
6
|
6
|
6
|
7
|
7
|
|
Switch to:
Switch to:
See Also
Discover More
